BioControl (2015) 60, 725-746
of interest to a wider audience. We would welcome
contributions to the Discussion section (above tab) of this article.
Remember to log in or register (top right corner) before editing pages.
Impact of the omic technologies for understanding the modes of action of biological control agents against plant pathogens
BioControl 60 (6), 725-746
Abstract: The characterization of microbial biological control agents (MBCAs) is crucial to improve their efficacy and consistency as biopesticides. Powerful approaches to characterize MBCA's modes of action are provided by modern molecular technologies. This paper reviews improvements achieved in this subject by three "omics" approaches: namely the genomic, the transcriptomic and the proteomic approaches. The paper discusses the advantages and drawbacks of new molecular techniques and 'discovery driven' approaches to the study of the biocontrol properties against plant pathogens. Omics technologies are capable of: (i) identifying the genome, transcriptome or proteome features of an MBCA strain, (ii) comparing properties of strains/mutants with different biocontrol efficacy, (iii) identifying and characterizing genes, mRNAs and proteins involved in MBCA modes of action, and (iv) simultaneously studying the transcriptome or proteome of the plant host, the plant pathogen and the MBCAs in relation to their bi- or tri-trophic interactions.
(The abstract is excluded from the Creative Commons licence and has been copied with permission by the publisher.)
Link to article at publishers website
Database assignments for author(s): Monica Höfte, M. Haissam Jijakli, Ilaria Pertot
Research topic(s) for pests/diseases/weeds:
biocontrol - natural enemies
Research topic(s) for beneficials or antagonists:
molecular biology - genes
Pest and/or beneficial records:
|Trichoderma hamatum (antagonist)|
|Trichoderma atroviride (antagonist)|
|Pseudozyma flocculosa (mycoparasite)|
|Trichoderma virens (antagonist)|
|Trichoderma reesei (antagonist)|
|Pseudomonas protegens (antagonist)|